Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie, in collaboration with REGENXBIO Inc., is ...

The company is also focused on strategic capital deployment. It has already invested in GLP-1 drug substance and drug product ...

The share price of Shilpa Medicare (NSE: SHILPAMED) closed at Rs 909.90 on August 14, 2025, representing a slight increase of ...

Zydus Lifesciences Limited has announced its unaudited consolidated financial results for the first quarter ended June 30, ...

Recently, VivaVision Biotech (Zhejiang) Co., Ltd. (VivaVision) announced the appointment of Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS to its Scientific Advisory Board.

Patients with challenging diabetic macular edema may achieve anatomical gains and extended dosing intervals with bispecific faricimab.

AQUARIUS, the second Phase 3 study, is anticipated to initiate in the fourth quarter of 2025, pending funding availability. Long-term follow-up from the LUNA Phase 2 study continues, with two-year ...

Second-Quarter 2025 and Recent Selected Highlights: <li /> Total revenues of $63.7 million, a 30% increase over $48.

D-150 Phase 3 program in wet AMD advancing ahead of plan, with expected 4FRONT-1 data readout accelerated to H1 2027 from H2 2027 and 4FRONT-2 initiated ahead of schedulePresented positive 60-week res ...

June 30, 2025, expected to fund planned operations into 2028 EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage ...

New anti-VEGF agents for wet age-related macular degeneration can extend injection intervals to 3-5 months but may increase ...